S-1 Plus Irinotecan Not Recommended for S-1-Refractory Gastric Cancer

Share this content:
Consecutive use of S-1 plus irinotecan is not recommended as second-line treatment in advanced gastric cancer.
Consecutive use of S-1 plus irinotecan is not recommended as second-line treatment in advanced gastric cancer.

Consecutive use of S-1 plus irinotecan is not recommended as second-line treatment in patients with advanced gastric cancer who are refractory to S-1-based first-line chemotherapy, a new study published online ahead of print in the journal Annals of Oncology has shown.

S-1 is an oral fluoropyrimidine used in combination with cisplatin for the first-line treatment of patients with advanced gastric cancer in Japan.

For the study, researchers sought to evaluate whether the consecutive use of S-1 plus irinotecan improves survival versus irinotecan alone as second-line treatment for advanced gastric cancer.

Researchers enrolled 304 patients and randomly assigned them to receive S-1 40-60 mg/m2 orally on days 1 to 14 plus irinotecan 150 mg/m2 IV on day 1 of a 21-day cycle or irinotecan alone on day 1 of a 14-day cycle.

RELATED: Loss-of-Function Variants Associated with Gastric Cancer Risk

Results showed that median overall survival was 8.8 months for S-1 plus irinotecan compared with 9.5 months for irinotecan alone (HR for death = 0.99; 95% CI: 0.78, 1.25; P=0.92).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters